Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

Thank You!

Your message has been sent.

Oops, message not sent.

Please make sure fields are complete.


CS Warrior Shares his Success with Ivosidenib

Hello my CS brothers and sisters! I wanted to tell you a story about my journey which might help some of you. Here are some details: –diagnosed in Feb 2017, Grade 1 pelvic CS, spread widely on and around the acetabulum. Offered a hemipelvectomy…

Read Article

More information on the Phase 2 Clinical Trail to Treat Conventional Chondrosarcoma

A CS Warrior on the Facebook Chondrosarcoma Support Group entered a new Phase 2 clinical trial yesterday specifically for unresectable and metastatic conventional CS that combines a histone deacetylase inhibitor Belinostat (FDA approved for a type…

Read Article

September is Childhood Cancer Awareness Month

In September, we honor the gold ribbon in recognition of Childhood Cancer Awareness Month! ✨ Did you know cancer is the second leading cause of death in children under the age of 15? In 2020, approximately 11,000 children ages 1-14 will be…

Read Article

A Clinical Trail for Unresectable and Metastatic Conventional Chondrosarcoma

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Brief Summary: This phase II trial studies how well belinostat and SGI-110…

Read Article

YouTube / Zoom Meeting: John Gross Presents Updates on Bone and Soft Tissue Tumor Classification

To view the video on YouTube, click here

Read Article

The Hunt for Predictive Biomarkers to Treat Soft Tissue Sarcomas

Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed. Gary K….

Read Article

Another Potential Medication to Treat Chondrosarcoma

Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency Abstract One of the crucial challenges in the clinical management of cancer is resistance to chemotherapeutics. Multidrug resistance (MDR) has been intensively studied,…

Read Article

Literature Review on the Effectiveness of Pazopanib (Votrient)

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma Warren Chow, MD1; Paul Frankel, PhD2; Chris Ruel, PhD2; Dejka M. Araujo, MD3; Mohammed Milhem, MBBS4; Scott Okuno, MD5; Lee…

Read Article

Contact Information

If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.

**A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**

Send a Message